The European Commission approved Novartis’ Mayzent for the treatment of adult patients with secondary progressive multiple sclerosis (SPMS) with active disease evidenced by relapses or imaging features of inflammatory activity.

The U.S. Food and Drug Administration approved Vumerity (diroximel fumarate) – a novel oral fumarate with a distinct chemical structure – for the treatment of relapsing forms of multiple sclerosis.

EMD Serono, a unit of Merck KGaA, announced that the U.S. FDA approved Mavenclad (cladribine) for adults with relapsing-remitting multiple sclerosis and active secondary progressive disease.

The U.S. FDA accepted Novartis’ New Drug Application for the investigational oral, once-daily siponimod (BAF312) for the treatment of secondary progressive multiple sclerosis in adults.